| Drug General Information |
| Drug ID |
D06EGV
|
| Former ID |
DNCL003806
|
| Drug Name |
LY2801653
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 2 |
[1]
|
|---|
| Company |
Lilly
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C30H22F2N6O3
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Hepatocyte growth factor receptor |
Target Info |
Modulator |
[2],
[3]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Adherens junction
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Malaria
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Pathway Interaction Database
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
Syndecan-1-mediated signaling events
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
FGF signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Sema4D mediated inhibition of cell attachment and migration
|
|
WikiPathways
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Signaling Pathways in Glioblastoma
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01285037) A Study of LY2801653 in Advanced Cancer. U.S. National Institutes of Health. |
|---|
| REF 2 | LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44. |
|---|
| REF 3 | Clinical pipeline report, company report or official report of Eli Lilly. |
|---|
